Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Govt Revision of Stent...

    Govt Revision of Stent prices: Industry woes but Consumers Rejoice

    Written by Ruby Khatun Khatun Published On 2018-02-13T14:14:26+05:30  |  Updated On 13 Feb 2018 2:14 PM IST
    Govt Revision of Stent prices: Industry woes but Consumers Rejoice

    New Delhi: Almost a year after it slashed rates of coronary stents by up to 85 percent, the NPPA on Monday revised the ceiling prices of bare metal stents and drug-eluting ones.


    In the case of bare metal stents (BMS), the government has increased the prices from current Rs 7,400 to Rs 7,660. On the other hand price of drug-eluting stents (DES) has come down to Rs 27,890 from Rs 30,180.




    New stent prices hihghlights;
    1-DES: 27890 ex GST
    BMS: 7660 ex GST
    2- No sub categories in DES
    3- Trade margin capped at 8%
    4-Prices of catheters etc to be mentioned in billing separately
    5- order Valid till 31/3/2019
    *Present price DES: 30180
    BMS: 7400


    — NPPA~India?? (@nppa_india) February 12, 2018



    The revised prices will be effective from today, the national pharmaceutical pricing authority (NPPA) said in a notification. The ceiling prices shall also be applicable to all the stocks of coronary stents available for sale in the trade channel, it added.


    The NPPA said it has been decided that there is no case for sub-classification of DES in the light of lack of enough clinical evidence to support the superiority of one DES or other. The regulator said after intensive deliberations on all the issues and available information/market statistics at its disposal, it was of the unanimous view that "cardiac stents being an essential drug under Schedule I of DPCO, 2013 and part of NLEM, 2015 having paramount importance on public health needs to continue to be kept under price regulation in larger public interest".








    The manufacturers may add goods and services tax and no other charges in the calculation of MRP, if they have actually paid such taxes or if it is payable to the government on the ceiling price specified, it added.The notification also said wherever institutions such as hospitals, nursing homes and clinics performing angioplasty procedures using coronary stents are billing directly to the patients, they shall be required to comply with the ceiling prices notified and follow the applicable provisions of the DPCO, 2013.







    The regulator also directed all the manufacturers to continue to ensure the availability of all the brands of coronary stents and ensure that no disruption is caused in the supply chain because of printing new MRPs.


    The ceiling prices as specified the order are inclusive of 8 percent maximum permissible trade margin which is sacrosanct and no additional charge shall be charged from the consumer/patient except applicable goods and services tax, if any, paid or payable, it added.


    The ceiling price fixed shall be applicable till March 31, 2019, unless revised by another notification, the notification said.


    Moving away from cardiac stents, NPPA also said that based on available data from the official sources and manufacturer/importer, the trade margins for the supply of cardiac balloon catheter is as high as 405 percent over the import cost.


    It was 292 percent for a cardiac drug-eluting balloon or cutting balloon, it added.

















































    Sl NoParticulars Average Margin %
    (MRP–import price)
    Average Margin % (MRP - PTD)
    (1)(2)(3)(4)
    1Cardiac Balloon Catheter405%234%
    2Cardiac Guidewire158%112%
    3Cardiac Guiding Catheter295%93%
    4Cardiac Drug Eluting Balloon or Cutting Balloon292%140%
    5Cardiac Guiding Catheter – Special feature172%62%



    Industry Response


    Mixed reactions were visible over the Monday's price cap by the government.


    Welcoming the decision, The All India Drug Action Network (AIDAN) stated, "We are glad that the government did not cave to a massive pressure that was being exerted by the industry for differential pricing without any scientific basis. We are further encouraged that the NPPA has shared data on the huge trade margins involved in catheters, balloons, and guidewires, expansion of price control to these devices is a necessary step to making procedures like angioplasty/angiogram more affordable and accessible to patients."


    AIDAN has also demanded that the NPPA should write to the CCI to conduct an investigation on the large hospital chains for abusing their dominant position and overcharging for angioplasties post the price cap.


    Welcoming the decision, Rajiv Nath, forum coordinator, Association of Indian Medical Device Industry (AiMeD) tweeted




    V R happy with NPPA’s new decision to continue with their directive on price cap by not getting swayed by the lobby of overseas multi-national manufacturers.Single category DES is scientific,continuation of the above stand gives confidence to Indian mfrs, v assure cooperation


    — AiMeD (@MiIAiMeD) February 12, 2018


    While the move was in general welcomed by the healthcare professionals and the consumers, the move was slammed by the stent manufactures, who said that such limit is going to hinder innovation in the market and prevent manufacturers from introducing new and advances stents for the Indian patients. Stent Manufacturers had demanded a differential pricing for different class of stents and were disappointed when the government ignored their demands


    Read Also: Differential Pricing for Different classes of Stents: Manufactures tell NPPA

    The decision is disappointing. Will limit patient choice and the availability of innovative technologies in the market. The only saving grace in the order is NPPAs' expression that it is open to receiving stakeholder views. Taking this expression as earnest, we will stay engaged. pic.twitter.com/zbw63ma7if Medical Technology Association of India (MTaI) has shown their disappointment over the new decision of the government. Mr. Pavan Choudary, director general of MTaI has tweeted



    — MTaI (@mtaiorg) February 12, 2018


    (AIMED)AIDANAll India Drug Action NetworkAssociation of Indian Medical Device Industrybare metal stentsCardiac stentsceiling pricescoronary heart diseasesCoronary StentsDESDPCODrug Eluting Stentsheart diseasesMedical Technology Association of IndiaMTaINational Pharmaceutical Pricing AuthorityNLEMNPPARajiv NathStent
    Source : With Agency Inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok